Ambrx
About
Ambrx develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance.
- 101 - 250
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- $45M
- Industries
- Biopharma,Biotechnology,Health Care,Life Science,Therapeutics
- Founded date
- Jan 1, 2003
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 4, 2016 | Series Unknown | $45M | 1 | — | — | Detail |
| Apr 1, 2009 | Series D | $10M | 1 | — | — | Detail |
| Jul 5, 2006 | Series C | $52M | 1 | — | — | Detail |
| Jan 25, 2006 | Series B | $5M | 1 | — | — | Detail |
| Mar 21, 2005 | Series A | $23.44M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series Unknown |
Versant Ventures
|
— | Series D |
